Kaur P, Sharma P, Bhatia P, Singh M
Front Oncol. 2024; 14:1445794.
PMID: 39600630
PMC: 11590065.
DOI: 10.3389/fonc.2024.1445794.
Qu Y, Gao N, Zhang S, Gao L, He B, Wang C
MedComm (2020). 2024; 5(9):e715.
PMID: 39252821
PMC: 11381670.
DOI: 10.1002/mco2.715.
Liu L, Ma L, Liu H, Zhao F, Li P, Zhang J
mSystems. 2024; 9(10):e0078824.
PMID: 39235366
PMC: 11494991.
DOI: 10.1128/msystems.00788-24.
Li F, Li W
Biomolecules. 2024; 14(7).
PMID: 39062595
PMC: 11275166.
DOI: 10.3390/biom14070881.
Hong L, Herjan T, Chen X, Zagore L, Bulek K, Wang H
J Exp Med. 2024; 221(7).
PMID: 38861022
PMC: 11167376.
DOI: 10.1084/jem.20231442.
Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
Zhang Y, Ling Y, Zhou Y, Shi X, Shen F, Zhou J
Cancer Control. 2024; 31:10732748241256819.
PMID: 38755968
PMC: 11102699.
DOI: 10.1177/10732748241256819.
Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.
Saw P, Song E
Cell Rep Med. 2024; 5(5):101555.
PMID: 38744276
PMC: 11148805.
DOI: 10.1016/j.xcrm.2024.101555.
The identification of a N-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma.
Mao X, Chen X, Xu Z, Ding L, Luo W, Lin Y
Aging (Albany NY). 2024; 16(9):7774-7798.
PMID: 38696324
PMC: 11131986.
DOI: 10.18632/aging.205782.
Functional Impacts of Epitranscriptomic mA Modification on HIV-1 Infection.
Phillips S, Mishra T, Huang S, Wu L
Viruses. 2024; 16(1).
PMID: 38257827
PMC: 10820791.
DOI: 10.3390/v16010127.
The epitranscriptome of high-grade gliomas: a promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses.
Ramsoomair C, Ceccarelli M, Heiss J, Shah A
J Transl Med. 2023; 21(1):893.
PMID: 38071304
PMC: 10709919.
DOI: 10.1186/s12967-023-04725-z.
N-Methyladenosine in Vascular Aging and Related Diseases: Clinical Perspectives.
Li C, Liu L, Li S, Liu Y
Aging Dis. 2023; 15(4):1447-1473.
PMID: 37815911
PMC: 11272212.
DOI: 10.14336/AD.2023.0924-1.
Ghost authors revealed: The structure and function of human N -methyladenosine RNA methyltransferases.
Breger K, Kunkler C, OLeary N, Hulewicz J, Brown J
Wiley Interdiscip Rev RNA. 2023; :e1810.
PMID: 37674370
PMC: 10915109.
DOI: 10.1002/wrna.1810.
The Regulation of m6A Modification in Glioblastoma: Functional Mechanisms and Therapeutic Approaches.
Deacon S, Walker L, Radhi M, Smith S
Cancers (Basel). 2023; 15(13).
PMID: 37444417
PMC: 10340774.
DOI: 10.3390/cancers15133307.
Deciphering glioma epitranscriptome: focus on RNA modifications.
Piperi C, Markouli M, Gargalionis A, Papavassiliou K, Papavassiliou A
Oncogene. 2023; 42(28):2197-2206.
PMID: 37322070
DOI: 10.1038/s41388-023-02746-y.
m6A Modification-Association with Oxidative Stress and Implications on Eye Diseases.
Ni Y, Zhang H, Chu L, Zhao Y
Antioxidants (Basel). 2023; 12(2).
PMID: 36830067
PMC: 9952187.
DOI: 10.3390/antiox12020510.
The m6A methyltransferase METTL16 negatively regulates MCP1 expression in mesenchymal stem cells during monocyte recruitment.
Zhang Z, Xie Z, Lin J, Sun Z, Li Z, Yu W
JCI Insight. 2023; 8(6).
PMID: 36795489
PMC: 10070103.
DOI: 10.1172/jci.insight.162436.
The Role of N-Methyladenosine in Inflammatory Diseases.
Xu H, Lin C, Yang J, Chen X, Chen Y, Chen J
Oxid Med Cell Longev. 2022; 2022:9744771.
PMID: 36578520
PMC: 9792239.
DOI: 10.1155/2022/9744771.
RNA modifications in cardiovascular health and disease.
Gatsiou A, Stellos K
Nat Rev Cardiol. 2022; 20(5):325-346.
PMID: 36471164
DOI: 10.1038/s41569-022-00804-8.
RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease.
Birgaoanu M, Sachse M, Gatsiou A
Cardiovasc Drugs Ther. 2022; 37(2):401-411.
PMID: 36239832
PMC: 9561330.
DOI: 10.1007/s10557-022-07391-3.
The roles and mechanisms of epigenetic regulation in pathological myocardial remodeling.
Zhao K, Mao Y, Li Y, Yang C, Wang K, Zhang J
Front Cardiovasc Med. 2022; 9:952949.
PMID: 36093141
PMC: 9458904.
DOI: 10.3389/fcvm.2022.952949.
